3 Catalysts Bristol-Myers Squibb Investors Need to Watch

3 Catalysts Bristol-Myers Squibb Investors Need to Watch

Shares of pharmaceutical giant Bristol-Myers Squibb have soared more than 40% since the start of 2013, and investor confidence in this high-flying stock is still high. However, in the world of health care investing, catalysts can either push shares up further or cool the market's optimism.

In the following video, a segment from the The Motley Fool's health care show Market Checkup, analysts Max Macaluso and David Williamson discuss three key catalysts that Bristol-Myers investors must watch. Among them are results from its oncology pipeline, the Food and Drug Administration decision on its type 2 diabetes drug Forxiga -- which it shares with AstraZeneca and could compete with Johnson & Johnson's Invokana in the U.S. market -- and its virology program, which has lost ground to biotech Gilead Sciences .

One of the best parts of owning big pharma stocks like Bristol is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article 3 Catalysts Bristol-Myers Squibb Investors Need to Watch originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.